There are 7 terms under the parent term 'Cancer' in the ICD-10-CM Alphabetical Index. Cancer - see also Neoplasm, by site, malignant bile duct type liver C22.1 blood - see Leukemia breast C50.91- - see also Neoplasm, breast, malignant hepatocellular C22.0 lung C34.90- - see also Neoplasm, lung, malignant ovarian C56.9- - see also Neoplasm ovary, malignant unspecified site (primary) C80.1
STOMACH | |
---|---|
C16.0 | Malignant neoplasm of cardia |
D13.1 | Benign neoplasm of stomach |
Z85.020* | Personal history of malignant carcinoid tumor of stomach |
Z85.028* | Personal history of other malignant neoplasm of stomach |
Search the full ICD-10 catalog by:
The ICD-10-CM is a catalog of diagnosis codes used by medical professionals for medical coding and reporting in health care settings. The Centers for Medicare and Medicaid Services (CMS) maintain the catalog in the U.S. releasing yearly updates.
The new codes are for describing the infusion of tixagevimab and cilgavimab monoclonal antibody (code XW023X7), and the infusion of other new technology monoclonal antibody (code XW023Y7).
Malignant (primary) neoplasm, unspecified C80. 1 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM C80. 1 became effective on October 1, 2021.
1 Malignant (primary) neoplasm, unspecified and C79. 9 Secondary malignant neoplasm of unspecified site. A diagnosis of metastatic cancer not otherwise specified (NOS) is used most often when diagnostic tests were not completed.
ICD-10 code Z51. 11 for Encounter for antineoplastic chemotherapy is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
ICD-9-CM Diagnosis Code 199.1 : Other malignant neoplasm without specification of site.
Any mention of extension, invasion, or metastasis to another site is coded as a secondary malignant neoplasm to that site. The secondary site may be the principal or first-listed with the Z85 code used as a secondary code.
1. If the documentation states the cancer is a metastatic cancer, but does not state the site of the metastasis, the coder will assign a code for the primary cancer, followed by code C79. 9 secondary malignant neoplasm of unspecified site.
Encounter for antineoplastic immunotherapyICD-10 code Z51. 12 for Encounter for antineoplastic immunotherapy is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
11 or Z51. 12 is the only diagnosis on the line, then the procedure or service will be denied because this diagnosis should be assigned as a secondary diagnosis. When the Primary, First-Listed, Principal or Only diagnosis code is a Sequela diagnosis code, then the claim line will be denied.
Z85. 3 can be billed as a primary diagnosis if that is the reason for the visit, but follow up after completed treatment for cancer should coded as Z08 as the primary diagnosis.
A malignant neoplasm (NEE-oh-plaz-um) is another term for a cancerous tumor. The term “neoplasm” refers to an abnormal growth of tissue. The term “malignant” means the tumor is cancerous and is likely to spread (metastasize) beyond its point of origin.
ICD-10 Code for Squamous cell carcinoma of skin, unspecified- C44. 92- Codify by AAPC.
C18. 9 - Malignant neoplasm of colon, unspecified. ICD-10-CM.
When a primary malignancy has been previously excised or eradicated from its site and there is no further treatment directed to that site and there is no evidence of any existing primary malignancy, a code from category Z85, Personal history of malignant neoplasm, should be used to indicate the former site of the malignancy .
Use a malignant neoplasm code if the patient has evidence of the disease, primary or secondary, or if the patient is still receiving treatment for the disease. If neither of those is true, then report personal history of malignant neoplasm.
Uncertain diagnosis. Do not code diagnoses documented as “probable”, “suspected,” “questionable,” “rule out,” or “working diagnosis” or other similar terms indicating uncertainty. Rather, code the condition (s) to the highest degree of certainty for that encounter/visit, such as symptoms, signs, abnormal test results, or other reason for the visit. ...
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion '), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous such as tumors in different quadrants of the same breast, codes for each site should be assigned.
When a primary malignancy has been previously excised or eradicated from its site and there is no further treatment directed to that site and there is no evidence of any existing primary malignancy at that site, a code from category Z85, Personal history of malignant neoplasm, should be used to indicate the former site of the malignancy. Any mention of extension, invasion, or metastasis to another site is coded as a secondary malignant neoplasm to that site. The secondary site may be the principal or first-listed with the Z85 code used as a secondary code.
Chapter 2 of the ICD-10-CM contains the codes for most benign and all malignant neoplasms. Certain benign neoplasms , such as prostatic adenomas, may be found in the specific body system chapters. To properly code a neoplasm, it is necessary to determine from the record if the neoplasm is benign, in-situ, malignant, or of uncertain histologic behavior. If malignant, any secondary ( metastatic) sites should also be determined.
Code C80.0, Disseminated malignant neoplasm, unspecified, is for use only in those cases where the patient has advanced metastatic disease and no known primary or secondary sites are specified. It should not be used in place of assigning codes for the primary site and all known secondary sites.
When a pregnant woman has a malignant neoplasm, a code from subcategory O9A.1 -, malignant neoplasm complicating pregnancy, childbirth, and the puerperium, should be sequenced first, followed by the appropriate code from Chapter 2 to indicate the type of neoplasm. Encounter for complication associated with a neoplasm.
There are also codes Z85.6, Personal history of leukemia, and Z85.79, Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues. If the documentation is unclear as to whether the leukemia has achieved remission, the provider should be queried.
Code C80.1, Malignant ( primary) neoplasm, unspecified, equates to Cancer, unspecified. This code should only be used when no determination can be made as to the primary site of a malignancy. This code should rarely be used in the inpatient setting.
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere.
Sarcoma is a malignancy that begins in bone, cartilage, fat, muscle, blood vessels, or other connective or supportive tissue. Leukemia is a malignancy that starts in blood-forming tissue such as the bone marrow, and causes large numbers of abnormal blood cells to be produced and enter the blood.
The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes. Primary malignant neoplasms overlapping site boundaries.
A multi-axial classification of the site, morphology, behaviour, and grading of neoplasms.
Change description: Updates in nomenclature and Classification, with emphasis of changes on haematologic and neurologic neoplasms.
Published: Chinese, Czech, English, Finnish, Flemish/Dutch, French German, Japanese, Korean, Portuguese, Spanish, Romanian, Turkish
Correspondence tables are available between ICD-O revisions and between ICD-O revisions and ICD-9 and ICD-10.
There is an agreement between the World Health Organization and the College of American Pathologists that the ICD-O morphology classification will be used for the M-8000 to M-9989 codes in the morphology axis of SNOMED. A change of SNOMED in 1993 led to incompatibilities for non-neoplastic lesions.